Imperial College Of Science, Technology And Medicine

Imperial College of Science, Technology and Medicine, doing business as Imperial College London, is a UK-based international research institution that acts as prime recipient on federal research grants and as a subcontractor on collaborative federal grant awards, focusing on fundamental and applied scientific research across aerospace, materials science, biomedical, and advanced physics domains. The institution is a non-profit educational organization headquartered in London, United Kingdom, with no SBA set-aside certifications and no federal contract prime awards in the recent footprint.

Imperial College operates almost entirely on the federal grant side, not contracts. The institution serves 36 distinct federal agencies across a portfolio of 206 awards (148 prime, 72%; 58 sub, 28%), with combined potential value of $22.3 million and combined obligated dollars of $91.6 million — a 411% ratio indicating substantial drawdowns against multiyear grant agreements. The top four customer agencies by award count (Department of the Air Force with 35 awards, Department of the Navy with 33, National Institute of Allergy and Infectious Diseases with 29 awards worth $5.1 million combined potential value, and NIH broadly with 10 awards) account for 56% of all awards. By potential value, NIAID anchors the portfolio at $5.1 million (29 awards), followed by the Defense Advanced Research Projects Agency ($1.4 million, 2 awards) and the National Heart Lung and Blood Institute ($1.1 million, 9 awards), which together represent only 34% of combined potential value — reflecting a broad, distributed portfolio rather than customer concentration.

Recent grant activity shows variability: 11 awards in fiscal year 2022, peaked at 24 in fiscal year 2024, then declined to 17 in fiscal year 2025 and 5 in the first half of 2026. Thirteen awards (combined potential value $188 thousand) reach ultimate completion within the next twenty-four months, presenting modest recompete exposure. Imperial's capability footprint centers on federally funded basic and applied research: the Air Force Defense Research Sciences Program (CFDA 12.800) funds work on data-driven aircraft flight control, quantum cascade lasers, magnetic field probing, and plasma dynamics; the Navy's Office of Naval Research sponsors research on atom interferometry, self-healing materials, and ocean turbulence parameterization; NIAID funds vaccine development (Group A Streptococcus, influenza mucosal immunity) and structure-function analysis of bacterial secretion systems; the Defense Health Agency and Army Medical Research Command fund biomedical research on spinal cord injury repair and prostate cancer; and DARPA sponsors proof-of-concept and LINC program work. Representative prime grant awards include a $180,595 Air Force project grant (September 2025–February 2029) on gust-tolerant flight of super-maneuverable vehicles, a $506,232 Defense Health Agency project grant (September 2023–September 2026) on pharmacological and biomaterial interventions for spinal cord injury, and a $539,979 Army Medical Command grant (August 2021–August 2024) on monoclonal antibody targeting for axonal regeneration. On the contract side, Imperial holds a $188,000 purchase order (November 2022, ultimate completion July 2026) from a civilian agency shared services center for flight-ready seismometer sensors, and a $173,690 CDC purchase order (August 2021, completed May 2023) for research and analysis on diabetes preventive care services trends.

Imperial operates predominantly through grant sub-awards under prime recipients at US universities and research institutions. Named prime grantees include the University of Utah, University of New Mexico, University of North Carolina at Chapel Hill, the General Hospital Corporation, Vanderbilt University Medical Center, Duke University, Columbia University, Stanford University, Johns Hopkins University, Brigham and Women's Hospital, Cornell University, Brown University, and others. Across these arrangements, Imperial contributes specialized research expertise — biostatistical methods, glycan analysis, computational modeling, sample processing, cryoEM analysis, and molecular biology — typically led by named Imperial faculty (such as Prof. Stuart Haslam in structural glycobiology, Dr. Vanessa Sancho Shimizu in immunology, and Prof. Darryl Overby in bioengineering). The institution also subcontracts to Mission Support and Test Services LLC on Department of Energy Nevada National Security Site R&D support (awarded March 2026) and to Peraton Labs Inc. on DARPA's LINC program (awarded April 2025).

Service Contract Inventory reporting captures minimal activity: six SCI records (three prime, three as named subcontractor) spanning fiscal years 2022–2024 with zero invoiced revenue on prime records and a trajectory of 4.7 FTEs in FY2022, zero in FY2023, and 1.8 FTEs in FY2024. This sparse SCI footprint reflects Imperial's grant-centric posture; research grants above the SCI threshold are captured in the grant awards themselves, not in SCI. The institution operates a named subsidiary, I C Consultants Limited, registered as a foreign-owned for-profit business organization.

Imperial College's federal footprint is strictly research-grant driven, with no contract vehicles (GWACs, IDIQs, BPAs, agency schedules) and no recurring customer relationships across multiple years at the same agency. The institution competes for peer-reviewed research funding from defense, health, and science agencies and participates in collaborative research networks anchored by US academic prime recipients.